© 2022 MJH Life Sciences and Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
© 2022 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
July 20, 2022
Dr Matthew Lunning closes his discussion on DLBCL by highlighting unmet needs in the treatment landscape.
Matthew Lunning, DO, FACP, shares data from the RE-MIND2 trial and explains how it compares to the L-MIND trial.
A review of the methods and data from a clinical trial investigating a combination therapy for relapsed/refractory DLBCL.
Dr Matthew Lunning describes the available third- and subsequent-line treatments for patients with relapsed/refractory DLBCL (R/R DLBCL) who aren’t eligible for transplant.
An expert explains the options for patients with DLBCL who develop chemorefractory disease in second-line treatment.
Matthew Lunning, DO, FACP, presents the case of a 64-year-old man with diffuse large B-cell lymphoma (DLBCL) and shares his initial impressions.